5-甲基-3-氨基-4-氮杂异噁唑 | 40483-47-4

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 5-甲基-3-氨基-4-氮杂异噁唑
• 中文别名: 5-甲基-1,2,4-恶二唑-3-胺
• 英文名称: 5-methyl-[1,2,4]oxadiazol-3-ylamine
• 英文别名: 3-amino-5-methyl-1,2,4-oxadiazole；5-methyl-1,2,4-oxadiazol-3-amine
• CAS: 40483-47-4
• 化学式: C₃H₅N₃O
• mdl: MFCD08272077
• 分子量: 99.0922
• InChiKey: JEEUSAKCHSWJKO-UHFFFAOYSA-N

物化性质

• 熔点：
  117-119 °C
• 沸点：
  228.8±23.0 °C(Predicted)
• 密度：
  1.283±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  64.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090
• WGK Germany：
  3
• 危险标志：
  GHS07
• 危险性描述：
  H302,H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338
• 储存条件：
  2-8°C

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 5-Methyl-1,2,4-Oxadiazol-3-Amine
: CBR00048
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 40483-47-4

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
Skin irritation (Category 2), H315
Eye irritation (Category 2), H319
Specific target organ toxicity - single exposure (Category 3), Respiratory system, H335
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn, Xi Harmful, Irritant R22, R36/37/38
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
Harmful if swallowed.
Causes skin irritation.
Causes serious eye irritation.
May cause respiratory irritation.
Precautionary statement(s)
Avoid breathing dust.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Synonyms : 1,2,4-Oxadiazol-3-amine, 5-methyl
Formula : C3H5N3O
Molecular weight : 99,09 g/mol
CAS-No. : 40483-47-4
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
5-Methyl-1,2,4-oxadiazol-3-amine
CAS-No. 40483-47-4 Acute Tox. 4; Skin Irrit. 2; Eye <= 100 %
Irrit. 2; STOT SE 3; H302,
H315, H319, H335
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
5-Methyl-1,2,4-oxadiazol-3-amine
CAS-No. 40483-47-4 Xn, Xi, R22 - R36/37/38 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
No data available
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature 2 - 8 °C
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - No data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-甲基-3-氨基-4-氮杂异噁唑 、 2-三氟甲基苯甲酰氯 生成 N-(5-methyl-1,2,4-oxadiazol-3-yl)-2-(trifluoromethyl)benzamide
  参考文献：
  名称：

  唑到唑相互转化的研究 - 在邻位取代的 3-Aroylamino-5-methyl-1,2,4-oxadiazoles 和 3-Acetylaminos 之间的环简并平衡中不存在“初级空间效应”的有趣案例5-芳基-1,2,4-恶二唑的甲醇溶液

  摘要：

  已通过 1H NMR 在 CD3OD 和 tBuOK/CD3OD 中研究了标题反应。苯环上的取代基的电子效应分量表现出不同的贡献，这取决于是否考虑中性（“近极性效应”的强烈流行）或阴离子物种（“普通极性和近极性效应”之间的平衡）之间的平衡. “初级空间效应”不会显着影响反应性，可能是因为内部酰胺共轭的重要性。对于邻甲氧基衍生物，观察到了有趣的“特殊”邻近效应。(© Wiley-VCH Verlag GmbH, 69451 Weinheim, Germany, 2002)

  DOI：

  10.1002/1099-0690(200204)2002:8<1417::aid-ejoc1417>3.0.co;2-g
• 作为产物：
  描述：

  N-(4-苯基-1,2,5-恶二唑-3-基)乙酰胺 在 氨 作用下， 以 甲醇 为溶剂， 反应 1.5h， 以80%的产率得到5-甲基-3-氨基-4-氮杂异噁唑
  参考文献：
  名称：

  A Generalized and Efficient Synthesis of 3-Amino-, 3-(N-Alkylamino)-, 3-(N,N-Dialkylamino)-5-alkyl-1,2,4-oxadiazoles by Irradiation of 3-Alkanoylamino-4-phenyl-1,2,5-oxadiazoles (Furazans)

  摘要：

  在甲醇中，在氨的存在下，用波长为310纳米的紫外线照射3-烷基氨基-4-苯基-1,2,5-恶二唑（呋喃），可生成3-氨基、3-(N-烷基氨基)、3-(N,N-二烷基氨基)-5-烷基-1,2,4-恶二唑，产率极高。

  DOI：

  10.1055/s-1995-4031

文献信息

• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：CTXT PTY LTD

  公开号：WO2020002587A1

  公开（公告）日：2020-01-02

  A compound of formula (I), or a pharmaceutically acceptable salt thereof.

  式（I）的化合物，或其药用可接受的盐。
• (Chlorosulfonyl)benzenesulfonyl Fluorides—Versatile Building Blocks for Combinatorial Chemistry: Design, Synthesis and Evaluation of a Covalent Inhibitor Library
  作者：Kateryna A. Tolmachova、Yurii S. Moroz、Angelika Konovets、Maxim O. Platonov、Oleksandr V. Vasylchenko、Petro Borysko、Sergey Zozulya、Anastasia Gryniukova、Andrey V. Bogolubsky、Sergey Pipko、Pavel K. Mykhailiuk、Volodymyr S. Brovarets、Oleksandr O. Grygorenko

  DOI：10.1021/acscombsci.8b00130

  日期：2018.11.12

  Multigram synthesis of (chlorosulfonyl)benzenesulfonyl fluorides is described. Selective modification of these building blocks at the sulfonyl chloride function under parallel synthesis conditions is achieved. It is shown that the reaction scope includes the use of (hetero)aromatic and electron-poor aliphatic amines (e.g., amino nitriles). Utility of the method is demonstrated by preparation of the

  描述了（氯磺酰基）苯磺酰氟的多克合成。在平行合成条件下，实现了这些构件在磺酰氯官能团上的选择性修饰。结果表明，反应范围包括使用（杂）芳族和贫电子的脂族胺（例如氨基腈）。通过制备潜在用作共价片段的磺酰氟文库证明了该方法的实用性，这是通过计算机模拟和针对胰蛋白酶作为模型酶的体外筛选相结合来证明的。结果，鉴定了几种抑制剂，其活性与已知抑制剂相当。
• Targeting Nonsense: Optimization of 1,2,4-Oxadiazole TRIDs to Rescue CFTR Expression and Functionality in Cystic Fibrosis Cell Model Systems
  作者：Ivana Pibiri、Raffaella Melfi、Marco Tutone、Aldo Di Leonardo、Andrea Pace、Laura Lentini

  DOI：10.3390/ijms21176420

  日期：——

  Cystic fibrosis (CF) patients develop a severe form of the disease when the cystic fibrosis transmembrane conductance regulator (CFTR) gene is affected by nonsense mutations. Nonsense mutations are responsible for the presence of a premature termination codon (PTC) in the mRNA, creating a lack of functional protein. In this context, translational readthrough-inducing drugs (TRIDs) represent a promising approach to correct the basic defect caused by PTCs. By using computational optimization and biological screening, we identified three new small molecules showing high readthrough activity. The activity of these compounds has been verified by evaluating CFTR expression and functionality after treatment with the selected molecules in cells expressing nonsense–CFTR–mRNA. Additionally, the channel functionality was measured by the halide sensitive yellow fluorescent protein (YFP) quenching assay. All three of the new TRIDs displayed high readthrough activity and low toxicity and can be considered for further evaluation as a therapeutic approach toward the second major cause of CF.

  囊性纤维化（CF）患者在囊性纤维化跨膜传导调节蛋白（CFTR）基因受到无义突变影响时，会发展成疾病的严重形式。无义突变导致mRNA中存在过早终止密码子（PTC），从而导致功能性蛋白质的缺失。在这种情况下，通过诱导转录读穿药物（TRIDs）来纠正由PTCs引起的基本缺陷是一种有前途的方法。通过计算优化和生物筛选，我们发现了三种新的小分子化合物，表现出高读穿活性。这些化合物的活性已通过在表达无义-CFTR-mRNA的细胞中使用选择的分子治疗后评估CFTR表达和功能来验证。此外，通道功能通过卤化物敏感的黄色荧光蛋白（YFP）猝灭实验进行了测量。所有三种新的TRIDs显示出高读穿活性和低毒性，可被考虑进一步评估作为治疗CF第二主要原因的方法。
• Synthesis of 1-substituted 3-amino-1H-1,2,4-triazoles from ethyl N-(5-phenyl-1,2,4-oxadiazol-3-yl)formimidate
  作者：Jeff Shen、Haiming Zhang

  DOI：10.1016/j.tet.2015.06.094

  日期：2015.9

  efficient method for the synthesis of 1-substituted 3-amino-1H-1,2,4-triazoles has been developed. The desired 3-amino-1H-1,2,4-triazoles (3) were prepared in good to excellent yields from ethyl N-(5-phenyl-1,2,4-oxadiazol-3-yl)formimidate (1a) and anilines or amines (2) via a one-pot process involving formimidamide formation followed by a thermal monocyclic rearrangement. The benzoyl protecting group could

  已经开发了合成1-取代的3-氨基-1 H -1,2,4-三唑的通用且有效的方法。从N-（5-苯基-1,2,4-恶二唑-3-基）甲亚胺酸乙酯（1a）制备了所需的3-氨基-1 H -1,2,4-三唑（3），具有良好的收率。）和苯胺或胺（2）通过一锅法，包括形成甲酰胺并随后进行热单环重排。苯甲酰基保护基很容易通过硫酸促进的脱保护作用而除去。
• BICYCLOAMINE DERIVATIVES
  申请人：Ozaki Fumihiro

  公开号：US20090270369A1

  公开（公告）日：2009-10-29

  Compounds represented by formula (I) and pharmaceutically acceptable salts thereof have excellent sodium channel inhibitory action and are useful as therapeutic agents and analgesics for various kinds of neuralgia, neuropathy, epilepsy, insomnia, premature ejaculation and the like. wherein Q represents ethylene, etc., R 1 , R 2 and R 3 represent hydrogen, etc., X 1 represents C 1-6 alkylene, etc., X 2 represents C 1-6 alkylene, etc., A 1 represents a 5- to 6-membered heterocyclic group, etc., and A 2 represents C 6-14 aryl, etc.

  由式(I)表示的化合物及其药学上可接受的盐具有出色的钠通道抑制作用，并可用作治疗剂和各种神经痛、神经病、癫痫、失眠、早泄等的镇痛剂。其中Q代表乙烯等，R1、R2和R3代表氢等，X1代表C1-6烷基等，X2代表C1-6烷基等，A1代表5-至6-成员杂环基团等，A2代表C6-14芳基等。